Unicycive(US:UNCY) Prnewswireยท2025-09-15 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from March 29, 2024, to June 27, 2025 [1]. Group 1: Allegations and Class Period - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [1]. - It is claimed that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [1]. - As a result, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Group 2: Shareholder Actions - Shareholders who purchased shares of UNCY during the specified class period are encouraged to register for the class action by October 14, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - There is no cost or obligation for shareholders to participate in this class action [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].